Pfizer ’s Mylotarg receives FDA approval for acute myeloid leukaemia treatment
The US Food and Drug Administration (FDA) has granted approval to Pfizer ’s antibody-drug conjugate (ADC) Mylotarg (gemtuzumab ozogamicin) for the treatment of patients with acute myeloid leukaemia (AML).
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news
More News: Acute Leukemia | Acute Myeloid Leukemia | Food and Drug Administration (FDA) | Leukemia | Pfizer | Pharmaceuticals